Canada Canadian government to grant $3M for psilocybin research studies The aim is to expand the evidence base on psilocybin-assisted psychotherapy to inform practical policies and regulations Natalia Buendia CalvilloMay 5, 2022
Business Field Trip to split into two independent companies Current shareholders of the firm will receive shares of each company Natalia Buendia CalvilloMay 3, 2022
Culture Numinus announces Music as Medicine event series Series of concerts across the U.S. and Canada will explore music’s role in psychedelic-assisted therapy Ryan GarnerMay 3, 2022
Medical and Pharmaceutical Delic Labs granted permission to study psychedelics including LSD, MDMA The Vancouver-based research lab aims to increase understanding of the medical applications of psychedelic compounds Ryan GarnerApril 15, 2022
Business Numinus to enter US psychedelics market via $26.2M Novamind acquisition The transaction is expected to close around June Natalia Buendia CalvilloApril 12, 2022
Medical and Pharmaceutical Psilocybin temporarily disrupts stages of the sleep cycle : study But whether or not the disruption helps with the substance's antidepressant properties still needs further research Natalia Buendia CalvilloApril 11, 2022
Legalization Georgia advances bill to create psychedelic study group focused on Veterans’ mental health Lawmakers note that current therapeutic trials for substance use issues exclude people with a history of substance abuse Natalia Buendia CalvilloMarch 29, 2022
News Therapists’ personal experience important for patients undergoing psilocybin-assisted therapy: study Previous experience was rated more important than shared symptoms, gender or ethnicity Natalia Buendia CalvilloMarch 28, 2022
Business Universal Ibogaine hires ex-Canopy research director ahead of clinical trial application The firm owns rights to a treatment protocol used at a popular clinic in Cancun, Mexico Natalia Buendia CalvilloMarch 23, 2022
Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022